N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Income from Continuing Operations
-$37.9m
CAGR 3-Years
N/A
CAGR 5-Years
-50%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Income from Continuing Operations
-kr133.5m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-12%
B
Bergenbio ASA
OSE:BGBIO
Income from Continuing Operations
-kr152.3m
CAGR 3-Years
21%
CAGR 5-Years
5%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Income from Continuing Operations
-kr87.9m
CAGR 3-Years
-28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Income from Continuing Operations
kr7m
CAGR 3-Years
-53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Income from Continuing Operations
-kr18.7m
CAGR 3-Years
64%
CAGR 5-Years
45%
CAGR 10-Years
7%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Income from Continuing Operations?
Income from Continuing Operations
-37.9m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Income from Continuing Operations amounts to -37.9m USD.

What is Nykode Therapeutics ASA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-50%

Over the last year, the Income from Continuing Operations growth was 19%.

Back to Top